Targets › PROT
2 programs from 2 companies in 29 trials: 17 Phase 2, 7 Phase 3, 4 Phase 4, 1 Phase 1; Infectious disease; next expected readout Dec 2026.
Brain specific sodium (and chloride)-dependent proline transporter. Terminates the action of proline by its high affinity sodium-dependent reuptake into presynaptic terminals (Probable). (UniProt, Q99884)
Open in Phaseline: the race on PROT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Instituto Mexicano del Seguro Social | Darunavir Human immunodeficiency virus type 1 protease inhibitor | PROT, CYP3A4, POLR2A | Phase 4 | HIV Infection | Dec 2026 |
| Gilead Sciences | Lenacapavir Structural capsid protein inhibitor | CA, CPSF6, GAG, PROT, UNKNOWN, CAPSID | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection; HIV Pre-exposure Prophylaxis; HIV Infections; HIV-1-infection … | Mar 2027 |
HIV-1-infection (10) Pre-Exposure Prophylaxis of HIV Infection (7) HIV-1 Infection (3) HIV Infection (2) HIV Pre-exposure Prophylaxis (2) HIV Infections (1) HIV-1-Infection (1) HIV (1) HIV Prevention (1) Human Immunodeficiency Virus (1)
small molecule (1), mixed (1)
Instituto Mexicano del Seguro Social (1) Gilead Sciences (1)
CYP3A4 (1) POLR2A (1) CA (1) CPSF6 (1) GAG (1) UNKNOWN (1) CAPSID (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.